Pamela (Pam) Strode joined Fulcrum in September 2019. She comes to Fulcrum from Epizyme, where she served as senior vice president, regulatory affairs and quality assurance, and played a critical role in establishing the team’s regulatory affairs and quality assurance departments. At Epizyme, Pam directed multiple U.S. Fast Track and U.S./E.U. Orphan Drug Designations and also led the regulatory strategy and operations for several clinical trial applications and a New Drug Application (NDA). She brings more than 30 years of regulatory leadership for investigational and marketed products across multiple therapeutic areas, with increasing levels of responsibility at Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc. and Cerulean Pharma. Pam has a B.S. in microbiology from Cook College at Rutgers University and an M.S. in QA/RA from Temple University, where she also obtained a Drug Development Certificate.[/amoteam_text]